Ciloa Sas

CILOA’S CUSTOMIZED EXOSOMES FOR INNOVATIVE THERAPEUTICS Ciloa is the most experienced exosome-based R&D Company dedicated to the development of new high-potential bio-drugs. By overcoming undruggable targets, Ciloa supports your projects to create new therapeutic and new preventive solutions. Ciloa customizes in vivo exosomes to contain i) fully native membrane protein complexes (GPCRs, Kinase Receptors, Ion Channels, Viral Antigens, Transporters…) embedded in their membrane and ii) chosen cargo proteins inside their cytosol. Natural properties of exosomes combined with Ciloa in vivo disruptive technology allow to develop: - VIRUS-FREE candidate THERAPEUTIC VECTORS able to deliver specifically chosen cargos to any diseased organ. - ANTIBODIES AGAINST UNDRUGGABLE MEMBRANE PROTEIN COMPLEX TARGETS by unlocking all bottlenecks of the antibody development process. - ADJUVANT & VIRUS-FREE candidate VACCINES, thanks to the combination of perfect antigens with the potent natural adjuvant properties of exosomes. Ciloa works through Licensing and Partnerships.